Latest Factor VIII Stories
WAYNE, N.J., July 28, 2011 /PRNewswire/ -- Bayer HealthCare today announced the 2011 recipients of the Bayer Hemophilia Awards Program (BHAP). This year, the company has awarded nearly $2.5 million in funding to 18 recipients from 12 countries, including the U.S.
KYOTO, Japan, July 28, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc.
KING OF PRUSSIA, Pa., July 18, 2011 /PRNewswire/ -- CSL Behring has donated more than 1 million international units (IU) of von Willebrand factor (VWF)/Factor VIII (FVIII) replacement medication to patients through the World Federation of Hemophilia (WFH).
KING OF PRUSSIA, Pa., May 31, 2011 /PRNewswire/ -- CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.
KING OF PRUSSIA, Pa., May 19, 2011 /PRNewswire/ -- Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at an international medical congress on May 22, 2011.
MONTVILLE, N.J., and MONTREAL, April 28, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia (WFH) are announcing a three-year extension of Bayer's sponsorship agreement with WFH.
- An imitative word; an onomatopoetic word.